• Medical technology company Intelligent Bio Solutions has launched Arabic, Italian, and Spanish websites to support expansion into key international markets.
• The move opens digital access to over 1.4 billion people across Latin America, the Middle East, and Southern Europe.
• The rollout aligns with increased demand for non-invasive workplace drug testing and compliance tools.
• INBS’s flagship fingerprint sweat-based drug screening system is currently used by over 450 clients in 24 countries.
• The company plans a U.S. market launch in 2025 as it continues to develop additional biosensor applications.

Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is expanding its international footprint by launching localized websites in Arabic, Italian, and Spanish. The initiative is part of the firm’s strategy to boost commercial activity across high-potential regions with growing demand for workplace safety and compliance solutions (https://ibn.fm/odRAg).

The multilingual rollout is intended to remove key barriers to digital engagement and facilitate sales pipeline development across Latin America, the Middle East, and Southern Europe. Together, these areas represent over 1.4 billion people—a significant commercial audience for INBS’s fingerprint drug testing technology.

“This is not just a translation project; it’s a commercial growth engine,” said Harry Simeonidis, President and CEO of Intelligent Bio Solutions. The company believes that a localized online presence will not only attract more inbound traffic but also help convert interest into partnerships and sales by aligning with regional expectations and regulatory environments. “By localizing our online presence and sales infrastructure to make it ready for use by customers across the globe, we are building scalable access to high-potential markets. These initiatives are the foundation for strengthening distributor relationships, increasing lead generation, and facilitating faster market penetration worldwide,” Simeonidis added.

At the core of the company’s offering is the Intelligent Fingerprinting Drug Screening System, a portable solution that analyzes fingerprint sweat for substances including opiates, methamphetamine, cocaine, and cannabis. The system collects samples in seconds and delivers results in under ten minutes. Unlike traditional urine or saliva tests, INBS’s technology is designed to be hygienic, quick, and easy to deploy on-site.

The company currently has over 450 active accounts in 24 countries. Its clients include firms in sectors such as construction, logistics, manufacturing, mining and transportation, industries where safety compliance and rapid screening are essential.

According to INBS, the international response to its product has been encouraging, particularly after enhancements to its multilingual functionality. The reader interface now supports use in non-English-speaking settings, making it easier for international distributors and clients to adopt the platform.

This expansion comes at a time when several regions targeted by the company are experiencing increased regulatory scrutiny around workplace drug use. For example, countries in the Gulf Cooperation Council are tightening safety enforcement, creating a favorable environment for non-invasive, rapid testing tools. In Latin America, the drug screening market is forecast to reach $1.1 billion by 2030, according to market insights from Grand View Research. Spanish, one of the newly supported languages, is the official language in 20 countries in the region.

The Italian-language rollout is expected to support entry into the Southern European market, which shares similar occupational safety requirements and healthcare infrastructure dynamics with the rest of the European Union.

Alongside the language-specific websites, the company is increasing investment in digital lead generation and building a broader distributor network to support physical and operational presence in new territories. These steps are part of what INBS describes as a localization strategy, aligning its commercial operations with market-level demand.

Looking ahead, INBS is preparing to enter the multibillion-dollar U.S. market in 2025. The company believes the potential total addressable market in the U.S. for its drug testing technology is substantial. Market research undertaken by Grand View Research shows that the U.S. accounted for approximately 28% of the global drug screening market in 2023, reinforcing its position as one of the largest markets globally.

For more information, visit the company’s website at https://ibs.inc.

NOTE TO INVESTORS: The latest news and updates relating to INBS are available in the company’s newsroom at https://ibn.fm/INBS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN